

## **ISATUXIMAB**


# PATIENT CARD

#### DEAR PATIENT RECEIVING SARCLISA (ISATUXIMAB)

- Provide this card to healthcare providers before blood transfusion.
- Keep this card with you at all times and until at least 6 months after the last dose of isatuximab.
- 📕 lf you notice any side effects, talk to your doctor or pharmacist.

#### WARNING FOR HEALTHCARE PROVIDERS

- Please note this patient is receiving treatment with SARCLISA (isatuximab).
- This patient card contains important safety information that you need to be aware of before, during, and after treatment with isatuximab.
- Treatment with isatuximab binds to CD38 on red blood cells (RBCs) and is associated with a Risk of Interference with blood typing (positive indirect Coombs Test), which may persist for at least 6 months after the last isatuximab infusion.
- To avoid potential problems with RBC transfusion, you should perform blood type and screen tests prior to the first infusion of isatuximab. Phenotyping may be considered as per local practice.
- If treatment with isatuximab has already started and in the event of a planned transfusion, you should notify the blood bank that the patient is receiving isatuximab and its risk of Interference with Indirect Antiglobulin Tests.
- For additional information on isatuximab, please refer to the Package Insert (PI).



### sanofi